Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report [PDF]
BMJ Neurology OpenBackground Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system (CNS). Management during pregnancy is challenging due to limited safety data for disease-modifying therapies.Case presentation ...
Anu Jacob +3 more
doaj +2 more sources
Kidney MedicineRationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes
Kazuki Tanaka +2 more
exaly +3 more sources
A case report on the effective and safe use of ravulizumab in atypical hemolytic uremic syndrome during pregnancy [PDF]
BMC NephrologyBackground Atypical hemolytic uremic Syndrome (aHUS), a form of thrombotic microangiopathy (TMA), had a poor prognosis until the development of complement C5-inhibiting monoclonal antibodies, eculizumab and ravulizumab.
Abdulaziz Alkhaldi +4 more
doaj +2 more sources
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
Therapeutic Advances in Hematology, 2019 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert Stern, Nathan Connell
exaly +2 more sources
Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. [PDF]
PLoS ONEIntroductionComplement component 5 inhibitor therapies (C5ITs) for rare hematological, renal, and neurological diseases are associated with increased meningococcal infection risk. Robust risk mitigation measures include vaccination, drug safety programs,
Cynthia Carrillo Infante +1 more
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2021 Carmelo Gurnari,1,2 Ishani Nautiyal,1 Simona Pagliuca1,3 1Department of Translational Hematology and Oncology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedicine and Prevention, PhD in Immunology ...
Carmelo Gurnari, Simona Pagliuca
exaly +2 more sources
Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring. [PDF]
Ann Clin Transl NeurolAnnals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1301-1302, June 2026.
Saccà F, Pelto R.
europepmc +2 more sources
Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". [PDF]
Ann Clin Transl NeurolAnnals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Gerischer L +3 more
europepmc +2 more sources
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Neurology and Therapy, 2023 This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu +9 more
doaj +1 more source
Kidney Medicine, 2023 Rationale and Objective: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval.
Yan Wang +5 more
doaj +1 more source